<DOC>
	<DOCNO>NCT01273779</DOCNO>
	<brief_summary>Study evaluate safety potential benefit talactoferrin ( recombinant human lactoferrin ) addition standard care severe sepsis .</brief_summary>
	<brief_title>Safety Efficacy Talactoferrin Alfa Patients With Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Age great equal 18 year Onset severe sepsis within previous 24 hour Must receive antibiotic therapy Informed consent form sign patient authorize representative accord local rule regulation Able take liquid medication mouth feed tube Receipt investigational medication within 4 week prior participation study Pregnant breastfeeding Severe congestive heart failure Known severe HIV infection Presence severe burn Patients high dose immunosuppressant Patients whose death consider imminent Patients whose life expectancy concurrent illness le 6 month Severe hypoxic encephalopathy persistent vegetative state Severe liver disease Chronically bed bound Patient , legal representative patient 's primary physician commit provide full , aggressive life support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>sepsis</keyword>
	<keyword>talactoferrin</keyword>
	<keyword>lactoferrin</keyword>
	<keyword>recombinant human lactoferrin</keyword>
</DOC>